Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

December 21, 2022

Study Completion Date

December 21, 2022

Conditions
Diabetes type1Diabetes type2
Interventions
DEVICE

Device: Actiste 1.0 and the Companion app with TBL Backend

Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.

Trial Locations (1)

M6 6HD

Salford Royal Hospital Northern Care Alliance NHS Foundation Trust, Salford

All Listed Sponsors
collaborator

Brighter AB

INDUSTRY

lead

Northern Care Alliance NHS Foundation Trust

OTHER